Table of contents


On 26 August 2005, orphan designation (EU/3/05/303) was granted by the European Commission to Cellerix S.L., Spain, for human autologous mesenchymal adult stem cells extracted from adipose tissue for the treatment of anal fistula.

The sponsor changed name to Cellerix S.A. in September 2008 and then to TiGenix S.A.U. in February 2013.

For a list of the administrative updates to this public summary of opinion, please refer to the PDF document below.

Key facts

Active substance
Human autologous mesenchymal adult stem cells extracted from adipose tissue
Disease / condition
Treatment of anal fistula
Date of first decision
EU designation number

Sponsor's contact details

TiGenix S.A.U.
Marconi 1, Parque Tecnológico de Madrid
Tres Cantos
28760 Madrid
Tel. +34 91 804 92 64
Fax +34 91 804 92 63

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating